Dr. Reddy’s Laboratories Ltd: U.S. Product & Share Growth

Dr. Reddy's Laboratories Ltd (RDY)

Dr. Reddy’s Laboratories Ltd. (RDY) is an integrated global pharmaceutical company.  The company provides over-the-counter (OTC) drug products through its Global Generics Segment, pharmaceutical services and ingredients through its custom pharmaceutical services (CPS) business, and new chemical entities (NCE) through its Differentiated Formulations business. For fiscal year 2014, revenues were up 14% year over year to $2.2 billion, beating the Zacks Consensus Estimate of $2.15 billion.  However, earnings came in at $2.10 per American Depository Share (ADS), short of Zacks Consensus Estimate of $2.18. Research and Development (R&D) expenses increased 62% to $207 million during the fiscal year.  In addition, Dr. Reddy made 13 filings in the US, and on June 27th, Dr. Reddy announced it had launched Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg, and 60 mg, the generic equivalent of Cymbalta.  Cymbalta is one of the leading prescription drugs used to treat depression and anxiety, as it had sales in the U.S. of roughly $5.04 billion for the 12 months ending in April 2014, according to IMS Health.